Omnicell, Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. The filing also reports unaudited fourth-quarter results. Omnicell provides medication-management automation, pharmacy analytics, adherence solutions, and related services; it reorganized and reported as one operating segment beginning in 2019. Approximately 90% of FY2019 revenue came from the United States.
Financial performance
| Metric | FY2019 | FY2018 | Change |
|---|---|---|---|
| Revenue | $897.0 million | $787.3 million | +14% |
| Product revenue | $659.6 million | $569.6 million | +16% |
| Services and other revenue | $237.4 million | $217.7 million | +9% |
| Gross profit / margin | $436.9 million / 49% | $372.3 million / 47% | +17% gross profit |
| Operating income / margin | $78.4 million / 8.7% | $44.4 million / 5.6% | +77% operating income |
| Net income | $61.3 million | $37.7 million | +63% |
| Diluted EPS | $1.43 | $0.93 | +54% |
| Cash from operations | $145.0 million | $104.0 million | +$41.0 million |
FY2019 operating cash flow less purchases of property and equipment and capitalized software development was approximately $83.3 million. Investing activities used $61.7 million, including $45.8 million of capitalized software development costs and $15.9 million of property and equipment purchases.
At year-end, cash and cash equivalents were $127.2 million, versus $67.2 million; working capital was $246.2 million, versus $192.6 million; and the current ratio was 2.0, versus 1.9. Debt was $50.0 million, compared with $135.4 million of long-term debt reported at FY2018 year-end. The November 2019 refinancing established a $500 million five-year revolving facility, with an additional uncommitted facility of up to $250 million. Omnicell reported compliance with its debt covenants.
FY2019 fourth-quarter revenue was $248.3 million, versus $211.8 million in Q4 2018; operating income was $22.2 million, versus $18.9 million; and net income was $22.1 million, versus $14.8 million. Fourth-quarter diluted EPS was $0.51, versus $0.36.
Material changes and business drivers
- Product bookings increased 14% to $813 million from $716 million. Backlog rose to $588 million from $478 million; the company cautions that backlog is not necessarily indicative of future sales because configurations and installation schedules can change.
- Hardware and software growth—particularly XT Series automated dispensing systems and, to a lesser extent, XR2 central pharmacy systems—primarily drove product revenue growth. Services revenue benefited from a larger installed base and growth in Population Health, Performance Center, and subscription-based leasing.
- Gross margin improved, with management citing lower XT Series manufacturing ramp-up costs and economies of scale. Services mix and investment to support new products partially offset this benefit.
- Operating expenses increased 9% to $358.6 million, including higher headcount, consulting, and commissions. FY2019 included $34.0 million of share-based compensation.
- Research and development expense was $68.6 million, up from $64.8 million, as the company continued investment in automation, intelligence, and its cloud data platform.
Outlook, risks, and unusual items
The filing does not provide clear numerical revenue, earnings, or cash-flow guidance. Management describes continued investment in its “autonomous pharmacy” strategy, cloud and subscription offerings, XT Series replacement opportunities, central-pharmacy automation, and population-health solutions. It states that cash, expected operating cash flows, employee-plan proceeds, and available credit are expected to meet needs for at least the next twelve months.
- Execution and demand: New products may be delayed, fail to gain adoption, or encounter quality or interoperability issues. Equipment sales have long cycles, and installation delays can defer revenue recognition. Healthcare customer budgets and capital spending may fluctuate.
- Supply chain and public health: The company relies on limited or sole-source suppliers for certain components and packaging materials. It identified potential disruption to China-based suppliers following the coronavirus outbreak; the impact was uncertain at the filing date.
- Debt and financing: The revolving facility carries LIBOR-linked rates and restrictive covenants. Debt service, covenant compliance, and future financing availability could constrain flexibility.
- Data, regulatory, and legal exposure: Cloud services and patient information create cybersecurity, privacy, and compliance risks. A BIPA class action and product-liability litigation remained pending or possible; Omnicell said potential losses were reasonably possible but not probable and could not be reasonably estimated, so it recorded no accrual for the described matters.
- SEC inquiry: The company disclosed that the SEC had sought information in August 2019 about accounting processes and procedures. In February 2020, the SEC confirmed it had concluded its investigation and did not intend to recommend enforcement action.
- Tax and accounting items: FY2019 tax expense included a $7.4 million charge associated with internal legal-entity restructuring and intellectual-property transfers; the reported effective tax rate was 17%, compared with a tax benefit and negative 6% rate in 2018. The company adopted the new lease standard in 2019, adding lease right-of-use assets and liabilities to the balance sheet.
Most important facts for investors to verify
- Whether bookings and backlog convert into timely installations, recognized revenue, and cash collection.
- Whether improved gross and operating margins are sustained as product mix, subscription adoption, and investment spending evolve.
- Whether XT Series, XR2, IV compounding, and cloud-based offerings achieve expected customer uptake and quality performance.
- Whether supplier concentration, China-related disruption, and inventory valuation create delivery or margin pressure; inventory was $108.0 million at year-end.
- Debt terms, covenant headroom, interest-rate exposure, and the effect of equity issuance: the company sold approximately 460,000 shares under its at-the-market program for $38.5 million gross proceeds in 2019.
- Developments in BIPA and product-liability matters, and any changes in estimated legal exposure.
The independent auditor issued an unqualified opinion on the financial statements and on internal control over financial reporting as of December 31, 2019. The audit identified inventory valuation and capitalized software costs as critical audit matters.